Cyrano Therapeutics announced the launch of a Phase 1 study of CYR-064 intranasal theophylline in Parkinson’s disease patients that is being conducted by David Silvers of Gardens Neurology in Palm Beach, Florida. Cyrano is developing the theophylline nasal spray for the restoration of the sense of smell in patients with reduced or absent sense of smell.
In 2023, the company initiated a Phase 2 trial of CYR-064 in patients who lost their sense of smell following a viral infection, and that study is still underway, with top-line date expected later this year. In January 2024, Cyrano announced that it had closed a $9 million Series B fundraising to support that trial.
The Gardens Neurology study, titled “A Single Arm Feasibility Study for the Treatment of Parkinson’s Disease Related Hyposmia Using CYR-064 Theophylline Spray,” is expected to enroll 15-20 Parkinson’s patients with moderate-to-severe reduction in the ability to smell. Subjects will receive 2 sprays of CYR-064 in each nostril 2 times per day over 24 weeks and will be followed through 32 weeks. The title and study plan are similar to those of a trial of CYR-064 in Parkinson’s patients that is sponsored by the University of Nebraska.
Cyrano CEO Rick Geoffrion commented, “The potential to restore the sense of smell in Parkinson’s patients represents a significant step forward in addressing an often overlooked aspect of the disease that decreases a patient’s quality of life and contributes to the decline of their nutritional health. We are excited to support this important investigator-initiated study, which aligns with our mission to improve the lives of individuals living with chronic loss of smell and the associated loss of taste perception.”
Silvers said, “Hyposmia is a challenging and debilitating symptom for many Parkinson’s patients, and innovative approaches like CYR-064 are critically needed. We look forward to assessing this promising therapy’s potential to address a significant unmet need in Parkinson’s care.”
Read the Cyrano Therapeutics press release
